{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:21:17Z","timestamp":1790108477878,"version":"4.0.1"},"reference-count":44,"publisher":"JMIR Publications Inc.","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMIR Res Protoc"],"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are widely used in the treatment of non\u2013small cell lung cancer due to their precision, efficiency, and ease of use. However, skin rashes induced by EGFR-TKIs are the most common and earliest form of skin toxicity, often affecting the quality of life and treatment compliance of patients and leading to early discontinuation of therapy. These skin reactions may even impact cancer outcomes. In clinical practice, traditional Chinese medicine detoxification granules have shown effectiveness in relieving skin discomforts such as itching, pain, and burning caused by EGFR-TKI therapy. A prior single-arm trial investigating the treatment of targeted drug\u2013induced rashes demonstrated a sustained improvement in rash symptoms with an effectiveness rate of 80.77% and was well tolerated by patients.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n As an exploratory clinical study, this randomized controlled trial will preliminarily evaluate the potential efficacy and safety of jiedu xiaozhen (JDXZ) granules in managing EGFR-TKI\u2013related skin toxicities.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n This randomized controlled trial will be conducted at Shanxi Provincial Hospital of Traditional Chinese Medicine. A total of 94 patients with confirmed epidermal growth factor receptor gene\u2013mutated non\u2013small cell lung cancer who developed rashes after EGFR-TKI treatment will be enrolled. Patients will be randomly assigned to either a JDXZ traditional Chinese medicine group (group J) or a urea ointment group (group U). The primary outcome will be the severity of the rash as assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events grading. Secondary outcomes will include the WoMo (Wollenberg and Moosmann) score, numerical rating scale, Dermatology Life Quality Index scale, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 score, median progression-free survival, and changes in the levels of fibroblast growth factor 7 and hepatocyte growth factor in the blood. Adverse reactions will be recorded throughout the study. Data will be analyzed using SPSS.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The clinical trial registration was completed in October 2024. This study is currently underway. As of December 1, 2025, a total of 81 eligible participants had been enrolled, all of whom were assigned to groups following the randomization principle. Among them, 42 participants were allocated to the JDXZ group (with an additional 2 participants pending enrollment), and 39 to the control group. Based on the current progress, the estimated trial completion date has been extended to January 31, 2026.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n The results of this study may help develop an effective treatment for EGFR-TKI\u2013mediated rashes. The findings will be published in academic journals upon the completion of the trial.<\/jats:p>\n <\/jats:sec>","DOI":"10.2196\/79579","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T13:50:08Z","timestamp":1767016208000},"page":"e79579-e79579","source":"Crossref","is-referenced-by-count":1,"title":["Jiedu Xiaozhen Granules for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor\u2013Mediated Skin Toxicity: Protocol for a Randomized Controlled Trial"],"prefix":"10.2196","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8406-0792","authenticated-orcid":false,"given":"Shoujiang","family":"Hao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1452-8039","authenticated-orcid":false,"given":"Xiaoli","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shulan","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaojun","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7016-7530","authenticated-orcid":false,"given":"Likun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1010","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"issue":"6","key":"R1","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1080\/15384047.2018.1435222","article-title":"Small cell lung cancer transformation from EGFR-mutated lung adenocarcinoma: a case report and literatures review","volume":"19","author":"Liu","journal-title":"Cancer Biol Ther"},{"issue":"48","key":"R2","doi-asserted-by":"publisher","first-page":"78985","DOI":"10.18632\/oncotarget.12587","article-title":"The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis","volume":"7","author":"Zhang","journal-title":"Oncotarget"},{"issue":"9","key":"R3","doi-asserted-by":"publisher","first-page":"627","DOI":"10.3779\/j.issn.1009-3419.2022.101.47","article-title":"Consensus on application of third-generation EGFR-TKI in EGFR mutated NSCLC (2022 version)","volume":"25","author":"Chinese Society of Clinical Oncology (CSCO) Non-small Cell Lung Cancer Committee","journal-title":"Zhongguo Fei Ai Za Zhi"},{"issue":"11","key":"R4","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1158\/1078-0432.CCR-10-3408","article-title":"Effectiveness of tyrosine kinase inhibitors on \u201cuncommon\u201d epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer","volume":"17","author":"Wu","journal-title":"Clin Cancer Res"},{"issue":"suppl_1","key":"R5","doi-asserted-by":"publisher","first-page":"i3","DOI":"10.1093\/annonc\/mdx702","article-title":"Overview of current systemic management of EGFR-mutant NSCLC","volume":"29","author":"Hsu","journal-title":"Ann Oncol"},{"issue":"6","key":"R6","doi-asserted-by":"publisher","first-page":"537","DOI":"10.5582\/bst.2018.01246","article-title":"Update review of skin adverse events during treatment of lung cancer and colorectal carcinoma with epidermal growth receptor factor inhibitors","volume":"12","author":"Peng","journal-title":"Biosci Trends"},{"issue":"6","key":"R7","first-page":"2147","volume":"25","author":"Xueqi","journal-title":"World Sci Technol Mod Tradit Chin Med"},{"issue":"2","key":"R8","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3779\/j.issn.1009-3419.2019.02.01","article-title":"EGFR-TKI ADR management Chinese expert consensus","volume":"22","author":"Chinese Society of Lung Cancer, Chinese Anti-Cancer Association","journal-title":"Zhongguo Fei Ai Za Zhi"},{"issue":"21","key":"R9","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in -mutated advanced NSCLC","volume":"389","author":"Planchard","journal-title":"N Engl J Med"},{"issue":"2","key":"R10","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jaad.2014.07.032","article-title":"Cutaneous adverse effects of targeted therapies: part I: inhibitors of the cellular membrane","volume":"72","author":"Macdonald","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"R11","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.annonc.2020.11.005","article-title":"Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines","volume":"32","author":"Lacouture","journal-title":"Ann Oncol"},{"issue":"7","key":"R12","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1200\/JCO.2004.10.182","article-title":"Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor","volume":"22","author":"Saltz","journal-title":"J Clin Oncol"},{"issue":"1","key":"R13","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1200\/JCO.2005.04.057","article-title":"Practical management of patients with non-small-cell lung cancer treated with gefitinib","volume":"23","author":"Shah","journal-title":"J Clin Oncol"},{"issue":"5","key":"R14","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/j.ejca.2006.11.016","article-title":"Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors","volume":"43","author":"Galimont-Collen","journal-title":"Eur J Cancer"},{"issue":"22","key":"R15","doi-asserted-by":"publisher","first-page":"4646","DOI":"10.1200\/JCO.2004.02.168","article-title":"Complications of therapy in cancer patients: case 1. Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer","volume":"22","author":"Chang","journal-title":"J Clin Oncol"},{"issue":"11","key":"R16","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1016\/j.ejca.2010.04.028","article-title":"Characterisation of the cutaneous pathology in non-small cell lung cancer (NSCLC) patients treated with the EGFR tyrosine kinase inhibitor erlotinib","volume":"46","author":"Guttman-Yassky","journal-title":"Eur J Cancer"},{"issue":"1","key":"R17","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.lungcan.2012.06.009","article-title":"Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials","volume":"78","author":"Petrelli","journal-title":"Lung Cancer"},{"issue":"8","key":"R18","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1111\/jocd.15704","article-title":"Acneiform eruption induced by molecularly targeted agents in antineoplastic therapy: a review","volume":"22","author":"Yuan","journal-title":"J Cosmet Dermatol"},{"issue":"8","key":"R19","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00520-011-1197-6","article-title":"Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities","volume":"19","author":"Lacouture","journal-title":"Support Care Cancer"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2009.0074","article-title":"NCCN Task Force Report: management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer","volume":"7 Suppl 1","author":"Burtness","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"R21","doi-asserted-by":"publisher","first-page":"166","DOI":"10.2478\/raon-2013-0014","article-title":"A review of the treatment options for skin rash induced by EGFR-targeted therapies: evidence from randomized clinical trials and a meta-analysis","volume":"47","author":"Ocvirk","journal-title":"Radiol Oncol"},{"issue":"24","key":"R22","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.2169\/internalmedicine.5048-20","article-title":"Usefulness of rapid desensitization therapy for severe rash caused by molecularly targeted drugs used in the treatment of non-small-cell lung cancer","volume":"59","author":"Nagase","journal-title":"Intern Med"},{"issue":"12","key":"R23","doi-asserted-by":"publisher","first-page":"9728","DOI":"10.1074\/jbc.M110897200","article-title":"Retinoids suppress epidermal growth factor-associated cell proliferation by inhibiting epidermal growth factor receptor-dependent ERK1\/2 activation","volume":"277","author":"Sah","journal-title":"J Biol Chem"},{"issue":"12","key":"R24","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1111\/jdv.12365","article-title":"Retarded low\u2010dose doxycycline for EGFR or MEK inhibitor\u2013induced papulopustular rash","volume":"28","author":"Vaubel","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"R25","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.jaad.2016.01.019","article-title":"Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: a randomized, open-label trial","volume":"74","author":"Deplanque","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"R26","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/j.1365-2133.1996.tb06972.x","article-title":"Safety of long-term high-dose minocycline in the treatment of acne","volume":"134","author":"Goulden","journal-title":"Br J Dermatol"},{"key":"R27","unstructured":"Drugs and Lactation Database (LactMed\u00ae). National Institute of Child Health and Human Development; 2006. URL: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK501922\/ [Accessed 12-01-2026]"},{"issue":"4","key":"R28","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1517\/14740338.2016.1140743","article-title":"Long-term side effects of glucocorticoids","volume":"15","author":"Oray","journal-title":"Expert Opin Drug Saf"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejon.2021.101896","article-title":"The extent to which the last decade has yielded additional treatment options for EGFR-associated rash besides classic treatment with antibiotics and corticosteroids - a systematic review","volume":"50","author":"Papoui","journal-title":"Eur J Oncol Nurs"},{"issue":"9","key":"R30","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.3390\/ph17091176","article-title":"Insights from traditional Chinese medicine for restoring skin barrier functions","volume":"17","author":"Yang","journal-title":"Pharmaceuticals (Basel)"},{"key":"R31","unstructured":"Liu L Li X Hao S et al. A TCM composition containing large green leaves and its application in the treatment of targeted drug-related skin rash: CN114788847B.x. Chinese Patent Literature. Apr 7, 2023. URL: http:\/\/epub.cnipa.gov.cn\/patent\/CN114788847A [Accessed 25-05-2025]"},{"key":"R32","unstructured":"General Principles for Clinical Research of New Traditional Chinese Medicine Drugs. National Medical Products Administration. URL: http:\/\/www.nmpa.gov.cn\/xxgk\/ggtg\/qtggtg\/2015110312187.html [Accessed 03-11-2015]"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.13288\/j.11-2166\/r.2020.23.012","article-title":"A randomized, controlled, double-blind clinical study of the treatment of hand and foot skin reactions induced by multi-kinet inhibitors of antitumor targeted drugs (LC09 granules) combined with urea ointment","author":"Yu","journal-title":"J Trad Chin Med"},{"issue":"3","key":"R34","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1172\/JCI128678","article-title":"IL-36\u03b3 drives skin toxicity induced by EGFR\/MEK inhibition and commensal Cutibacterium acnes","volume":"130","author":"Satoh","journal-title":"J Clin Invest"},{"issue":"4","key":"R35","doi-asserted-by":"publisher","first-page":"545","DOI":"10.3390\/biom10040545","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitor erlotinib induces dry skin via decreased in aquaporin-3 expression","volume":"10","author":"Ikarashi","journal-title":"Biomolecules"},{"issue":"3","key":"R36","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.3892\/ijmm.2018.4046","article-title":"EGFR inhibitor gefitinib regulates barrier function in human epidermal keratinocytes via the modulation of the expression of claudins","volume":"43","author":"Fang","journal-title":"Int J Mol Med"},{"key":"R37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2023.124386","article-title":"Structural characterization and anti-inflammatory activity of polysaccharides from Astragalus membranaceus","volume":"241","author":"Chen","journal-title":"Int J Biol Macromol"},{"issue":"7","key":"R38","doi-asserted-by":"publisher","first-page":"e1800152","DOI":"10.1002\/cbdv.201800152","article-title":"Four natural compounds separated from folium isatidis: crystal structures and antibacterial activity","volume":"15","author":"Liao","journal-title":"Chem Biodivers"},{"issue":"9","key":"R39","doi-asserted-by":"publisher","first-page":"3960","DOI":"10.3390\/molecules28093960","article-title":"Anti-atopic effect of isatidis folium water extract in TNF-\u03b1\/IFN-\u03b3-induced HaCaT cells and DNCB-induced atopic dermatitis mouse model","volume":"28","author":"Min","journal-title":"Molecules"},{"key":"R40","volume":"15","author":"Liu","journal-title":"Chin J Exp Med"},{"issue":"9","key":"R41","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1001\/jama.2020.0812","article-title":"New insight on preventing EGFR inhibitor-induced adverse effects","volume":"323","author":"Hampton","journal-title":"JAMA"},{"issue":"21","key":"R42","doi-asserted-by":"publisher","first-page":"35193","DOI":"10.18632\/oncotarget.17060","article-title":"Predictive blood plasma biomarkers for EGFR inhibitor-induced skin rash","volume":"8","author":"Hichert","journal-title":"Oncotarget"},{"issue":"9","key":"R43","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1111\/j.1600-0625.2008.00715.x","article-title":"A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition","volume":"17","author":"Wollenberg","journal-title":"Exp Dermatol"},{"issue":"9","key":"R44","doi-asserted-by":"publisher","first-page":"4169","DOI":"10.1002\/cam4.2132","article-title":"Evaluation of EGFR inhibitor-mediated acneiform skin toxicity within the double-blind randomized EVITA trial: a thorough gender-specific analysis using the WoMo score","volume":"8","author":"Gaiser","journal-title":"Cancer Med"}],"container-title":["JMIR Research Protocols"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.researchprotocols.org\/2026\/1\/e79579","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T18:12:41Z","timestamp":1782843161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchprotocols.org\/2026\/1\/e79579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":44,"URL":"https:\/\/doi.org\/10.2196\/79579","relation":{},"ISSN":["1929-0748"],"issn-type":[{"value":"1929-0748","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]},"article-number":"v15i6e79579"}}